Rituximab This page contains brief information about rituximab and a collection of links to more information from the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the National Library of Medicine (NLM). US Brand Name(s): | ![](https://webarchive.library.unt.edu/eot2008/20090130235315im_/http://www.cancer.gov/images/spacer.gif) | Rituxan | ![](https://webarchive.library.unt.edu/eot2008/20090130235315im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20090130235315im_/http://www.cancer.gov/images/spacer.gif) | FDA Approved: | ![](https://webarchive.library.unt.edu/eot2008/20090130235315im_/http://www.cancer.gov/images/spacer.gif) | Yes |
Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
Information from the FDA
FDA Approval for Rituximab - Information from the FDA about the approval of this drug and the clinical trials that led to the approval.
Information from the NCIDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Clinical Trial Results: Rituximab Improves Outcomes for Patients with Chronic Lymphocytic Leukemia (01/14/2009) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Initial Treatment with Rituximab is a New Standard for Elderly Patients with B-Cell Lymphoma (07/10/2006) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Rituximab Benefits Younger Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma (05/03/2006) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Rituximab Helps Patients with Recurrent Lymphomas (10/26/2005) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Follicular Lymphoma Treatment Better with Rituximab (05/15/2005) - Important clinical trial results for this drug, background information, and how the trial was done.
Clinical Trial Results: Rituximab Improves Response Rate in Mantle Cell Lymphoma
(06/05/2004) - Important clinical trial results for this drug, background information, and how the trial was done.
Information from the NLM
MedlinePlus Information on Rituximab - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This NLM patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied. Clinical TrialsClinical Trials for Rituximab - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.
Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top |